Update information

Update information

March 2019: Olanzapine has been removed from recommendation 1.6.4 because the clinical need can now be met by a licensed product. The footnote to this recommendation stated that haloperidol and olanzapine do not have UK marketing authorisation for delirium treatment. However, haloperidol does now have marketing authorisation. Therefore, the footnote has been removed because it no longer applies to haloperidol.

Recommendation 1.5.1 has been amended because a delirium diagnosis is now confirmed using DSM-V.

ISBN: 978-1-4731-2992-4

  • National Institute for Health and Care Excellence (NICE)